Relapsing Remitting Multiple Sclerosis: Clinical Trials

9 trials for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 9 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 9
Phase 21Completed 1

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
ALKS 8700, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedBiogen5062017-03-152020-07-14
Vitamin D Supplementation in Multiple Sclerosis
Vitamin D3 - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedJohns Hopkins University1722012-03-012022-09-28
Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
MabCampath-1h - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedUniversity of British Columbia272011-03-012018-10-16
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Glatiramer acetate (GA), Placebo - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.14042010-06-222021-12-09
Safety of New Formulation of Glatiramer Acetate
Glatiramer Acetate, Experimental Glatiramer Acetate - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.1472009-07-012017-03-14
A Study for Patients With Relapsing Remitting Multiple Sclerosis
dirucotide, placebo - Relapsing Remitting Multiple Sclerosis
Phase 2 / Phase 3CompletedEli Lilly and Company2182006-11-012010-09-09
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.11552006-08-012011-10-10
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo
simvastatin, placebo - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedTehran University of Medical Sciences802005-04-012010-07-30
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Interferon beta 1-a, glatiramer acetate, placebo - Relapsing Remitting Multiple Sclerosis
Phase 3CompletedFred Lublin10082005-01-012014-04-03

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (9)  ·  Multiple Sclerosis (4)  ·  Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)

Broader conditions

Autoimmune Diseases of the Nervous System (8)  ·  Demyelinating Autoimmune Diseases, CNS (8)  ·  Demyelinating Diseases (8)  ·  Immune System Diseases (8)  ·  Nervous System Diseases (8)  ·  Autoimmune Diseases (7)  ·  Multiple Sclerosis (5)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Leukoencephalopathies (1)

Interventions

Glatiramer Acetate (4)  ·  Alemtuzumab (1)  ·  Cholecalciferol (1)  ·  Dimethyl Fumarate (1)  ·  Interferon beta-1a (1)  ·  MBP-8298 (1)  ·  Simvastatin (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (3)  ·  Biogen (1)  ·  Eli Lilly and Company (1)  ·  Fred Lublin (1)  ·  Johns Hopkins University (1)  ·  Tehran University of Medical Sciences (1)  ·  University of British Columbia (1)

Countries

United States (4)  ·  Poland (3)  ·  Bulgaria (2)  ·  Canada (2)  ·  Germany (2)  ·  Russia (2)  ·  Ukraine (2)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Georgia (1)  ·  Hungary (1)  ·  Iran (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Anthony Traboulsee, MD (1)  ·  Chen Duksin, MD (1)  ·  Ellen M Mowry, MD, MCR (1)  ·  Fred Lublin, MD (1)  ·  Giancarlo Comi, Prof (1)  ·  Mansooreh Togha, MD (1)  ·  Tom Smith, MD (1)

Results publications

PMID 20488825, PMID 23424159, PMID 24686106, PMID 25311447, PMID 27503905, PMID 31289819, PMID 31953790, PMID 32539719, PMID 32554770, PMID 33796143, PMID 34376508, PMID 34433679, PMID 34695274, PMID 34759712, PMID 34927308, PMID 36382118, PMID 37119208, PMID 37125397, PMID 37830451, PMID 38878121

NIH funding

2009 (1), 2017 (1), U01NS045719 (1)